Search - tctmd.com

Displaying 501 - 520 of 554

Sort: Relevancy | Date

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

News Daily News

In Print at Last, Early Cardioband Results Show Safety, Feasibility at 6 Months

Shelley Wood

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Shelley Wood

September 20, 2016

News Daily News

Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late

L.A. McKeown

September 16, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Todd Neale

September 02, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

Michael O'Riordan

August 18, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Antithrombotic Cocktail Fails to Provide Benefit, Increases Bleeding in A-Fib Patients Undergoing TAVR

Yael L. Maxwell

August 16, 2016

News Daily News

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

Yael L. Maxwell

August 10, 2016

News Daily News

CMR Confirms Link Between Moderate Aortic Regurgitation Post-TAVR and Poor Outcomes, Mortality

Yael L. Maxwell

August 05, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Daily News

Simple Risk-Scoring System Predicts Mortality After TAVR

Michael O'Riordan

July 25, 2016

Advertisement

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

In Print at Last, Early Cardioband Results Show Safety, Feasibility at 6 Months

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

TCTMD’s Top 10 Most Popular Stories for September 2016

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Elderly Asymptomatic Patients With Severe AS Are Often Treated Too Late

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Antithrombotic Cocktail Fails to Provide Benefit, Increases Bleeding in A-Fib Patients Undergoing TAVR

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

CMR Confirms Link Between Moderate Aortic Regurgitation Post-TAVR and Poor Outcomes, Mortality

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Simple Risk-Scoring System Predicts Mortality After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content